Diabetes and weight-loss drugs fall up to 90% in price as Indian generics take over

When the patent on semaglutide expired in India in March 2026, drugmakers including Sun Pharma, Zydus and Dr Reddy's flooded in with versions costing as little as Rs 1,290 a month — a fraction of the Rs 8,800–16,400 originator price. The medicine mimics a natural gut hormone that tells the brain it is full, and competition is finally putting it within reach of the millions of Indians managing obesity and type 2 diabetes.